GTHP may be undervalued if the Chinese go after it full blast and if financing comes in to re-address the FDA....for the 4th time. If "none of the above" takes place, then all we can do is wonder what number the protected technology would be sold to the highest bidder. One would have to wonder if a bidding process would even be contemplated in the U.S. with Merck already having a cervical cancer vaccine on the market.
News 
Market Data 
Discover 
